Endometrial injury for patients with endometriosis and polycystic ovary syndrome undergoing medically assisted reproduction: current data and a protocol

2018 ◽  
Vol 35 (1) ◽  
Author(s):  
Charalampos Siristatidis ◽  
Ioannis Rigos ◽  
Vasilios Pergialiotis ◽  
Vasilios Karageorgiou ◽  
Nikolaos Christoforidis ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Assisted Reproduction ◽  
Immune Cell ◽  
Positive Impact ◽  
Polycystic Ovary ◽  
Current Data ◽  
Ovary Syndrome ◽  
Medically Assisted Reproduction ◽  
Endometrial Injury ◽  
Published Evidence

Abstract We propose a study protocol capable of improving clinical outcomes following medically assisted reproduction (MAR) in infertile women with endometriosis and polycystic ovary syndrome (PCOS). The proposed research derives from the published evidence on the positive impact from endometrial injury (EI) and the beneficial nature of the intervention towards improved implantation rates. We primarily refer to the cluster of events and hypotheses, such as the mechanical cascade, the inflammatory response per se, the events accompanying wound healing, the immune cell recruitment and protein involvement, alterations in gene expression and the neo-angiogenesis theories, which have been previously investigated for this purpose. We are also exploring the possible problems in MAR cycles with negative outcomes in PCOS and endometriosis patients and we are proposing potential mechanisms on how this intervention might work. Our hypothesis states that the EI before the initiation of the MAR cycle can affect clinical pregnancy rates in patients with the aforementioned pathologies.

Genetic polymorphisms of reproductive hormones and their receptors in assisted reproduction technology for patients with polycystic ovary syndrome

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Yulia A. Koloda ◽  
Yulia V. Denisova ◽  
Natalia M. Podzolkova
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Assisted Reproductive Technologies ◽  
Polycystic Ovary ◽  
Ovarian Response ◽  
Reproductive Technologies ◽  
Reproductive Hormones ◽  
Current Data ◽  
Nucleotide Polymorphisms ◽  
Ovary Syndrome ◽  
Art Programs

Abstract Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in women of childbearing, which is defined by the accumulation of multiple, small fluid-filled ovarian cysts without the selection of a single dominant follicle. Most PCOS phenotypes are characterized by the absence of spontaneous ovulation, resistance toward ovulation inductors, the production of a large immature oocytes number, and the high prevalence of ovarian hyperstimulation syndrome, resulting in reduced assisted reproductive technologies (ART) programs effectiveness. The review analyses current data about the relationship between polymorphism genotypes of KISS genes, follicle stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH) and their receptors genes, gonadotropin-releasing hormone (GnRH), estrogen, and progesterone receptors genes, the PCOS risk and the features of ovarian response to stimulation during ART cycles. The use of single nucleotide polymorphisms (SNPs) as prognostic markers of ART programs outcomes would provide a personalized approach to the drugs and doses choice for ovarian stimulation and significantly increase the chance of pregnancy.

CYP19gene variants affect the assisted reproduction outcome of women with polycystic ovary syndrome

2013 ◽  
Vol 29 (5) ◽  
pp. 478-482 ◽  
Author(s):  
Leandros Lazaros ◽  
Nectaria Xita ◽  
Elissavet Hatzi ◽  
Atsushi Takenaka ◽  
Apostolos Kaponis ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Assisted Reproduction ◽  
Polycystic Ovary ◽  
Ovary Syndrome

Association between early embryo morphokinetics plus cumulus cell gene expression and assisted reproduction outcomes in polycystic ovary syndrome women

2019 ◽  
Vol 38 (2) ◽  
pp. 139-151 ◽  
Author(s):  
Nasim Tabibnejad ◽  
Mohammad Hasan Sheikhha ◽  
Nasrin Ghasemi ◽  
Farzaneh Fesahat ◽  
Mehrdad Soleimani ◽  
...  
Keyword(s):  
Gene Expression ◽  
Polycystic Ovary Syndrome ◽  
Assisted Reproduction ◽  
Polycystic Ovary ◽  
Cumulus Cell ◽  
Early Embryo ◽  
Ovary Syndrome ◽  
Cell Gene Expression ◽  
Cell Gene

Perinatal outcome of in vitro fertilization pregnancies in women with polycystic ovary syndrome by pregravid BMI

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Dzhamilyat Abdulkhalikova ◽  
Sara Korošec ◽  
Isaac Blickstein ◽  
Nataša Tul ◽  
Eda Vrtačnik Bokal ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Assisted Reproduction ◽  
Gestational Hypertension ◽  
Polycystic Ovary ◽  
Chronic Hypertension ◽  
Ovary Syndrome ◽  
Vitro Fertilization ◽  
Specific Subgroup ◽  
Reproductive Techniques

AbstractObjectivesGiven the adverse effects of either polycystic ovary syndrome (PCOS) or overweight/obesity, one could speculate that patients with both would fare worse than others. We sought to evaluate the relationship between pregravid BMI and pregnancy complications in PCOS patients conceived by assisted reproductive techniques (ART).MethodsMaternal and fetal/neonatal outcomes of singleton pregnancies after assisted reproduction in women with and without PCOS were compared by pregravid body mass index (BMI, <24.9 vs. ≥25 kg/cm2).ResultsThe study population comprised 185 with a BMI <24.9 kg/cm2 including 39 (21%) with PCOS and 146 (79%) without. We also included 84 patients with BMI ≥25 kg/cm2, involving 34 (40.5%) with PCOS and 50 (59.5%) without. PCOS (total 73 patients) was significantly more common among overweight/obese patients, OR 2.5 (95% CI 1.4, 4.4). Neonates >4,000 g were born only to the overweight/obese mothers in the PCOS group. A higher incidence of gestational diabetes, chronic hypertension, and gestational hypertension was related to pregravid overweight/obesity rather than PCOS.ConclusionsIn this specific subgroup of patients conceived after assisted reproduction, pregravid BMI>25 kg/cm2 rather than PCOS itself appears to be associated with GDM and hypertensive disorders.

scholarly journals The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome

Folia Medica ◽  
2018 ◽  
Vol 60 (4) ◽  
pp. 512-520 ◽  
Author(s):  
Panagiotis Chatzis ◽  
Konstantinos Tziomalos ◽  
Georgios C. Pratilas ◽  
Vasileios Makris ◽  
Alexandros Sotiriadis ◽  
...  
Keyword(s):  
Weight Loss ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Current Data ◽  
Reproductive Age ◽  
Metabolic Abnormalities ◽  
Ovary Syndrome ◽  
Antiobesity Agents ◽  
Androgen Levels

Abstract Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age. Obesity is frequently present in these patients and plays a key role in the pathogenesis of both the endocrine and metabolic abnormalities of the syndrome, particularly infertility, hyperandrogenism and insulin resistance (IR). Diet and exercise is the mainstay of management of obesity in patients with PCOS. In contrast, the eff ects of antiobesity agents on weight and on the obesityrelated characteristics of the syndrome remain unclear. The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population. Several studies reported that orlistat induces weight loss, improves IR and reduces androgen levels in PCOS. In contrast, data regarding the eff ects of the dose of liraglutide that is approved for the treatment of obesity (3 mg od) are very limited. Liraglutide 1.2-1.8 mg od results in weight loss in these patients but does not aff ect IR or androgen levels. Finally, there are no studies that evaluated naltrexone/bupropion in patients with PCOS and early studies reported conflicting results regarding the eff ects of naltrexone monotherapy on weight, IR and androgen levels. In conclusion, orlistat appears to have a role in the management of overweight and obese patients with PCOS whereas more studies are needed to clarify the role of liraglutide and naltrexone/bupropion.

Sign in / Sign up

Export Citation Format

Share Document